J Korean Orthop Assoc.
2023 Jun;58(3):238-244. 10.4055/jkoa.2023.58.3.238.
Clinical Outcomes of Myxofibrosarcoma
- Affiliations
-
- 1Department of Orthopaedic Surgery, Pusan National University Hospital, Pusan National University School of Medicine, Busan, Korea
- 2Departments of Radiology, Pusan National University Hospital, Busan, Korea
- 3Departments of Pathology, Pusan National University Hospital, Busan, Korea
- 4Department of Orthopaedic Surgery, Kosin University Gospel Hospital, Kosin University College of Medicine, Busan, Korea
- KMID: 2543271
- DOI: http://doi.org/10.4055/jkoa.2023.58.3.238
Abstract
- Purpose
Myxofibrosarcoma (MFS) is one of the most frequent recurrent soft tissue sarcomas and is generally a painless malignant soft tissue tumor that grows slowly in the limbs or surface torso. This study examined the clinical patterns and oncological results of patients with MFS.
Materials and Methods
From January 1, 2007 to December 31, 2020, 42 patients who underwent surgery after being diagnosed with MFS in the authors’ hospital and another hospital were examined. Their age, sex, tumor location and size, postoperative radiotherapy, magnetic resonance imaging (MRI), and pathological findings were analyzed retrospectively. Local recurrence, the remote metastasis occurrence time, follow-up period, and oncological results were analyzed. The Kaplan–Meier estimator survival-rate analysis method was used to analyze the survival rate.
Results
There were 28 males and 14 females, and the average age was 63 years (22–87 years). The location of the tumor was six cases in the hip, 15 cases in the thigh, two cases in the knee, four cases in the lower leg, four cases in the shoulder, four cases in the upper arm, two cases in the forearm, one case in the head & neck, one case in the lumbar spine, and one case in the retroperitoneal cavity, and the average size of the tumor was 7.03 (0.6–23.0) cm. The classifications at the time of diagnosis according to the American Joint Committee on Cancer stage were IA in three cases, IB in seven cases, II in 13 cases, IIIA in 11 cases, IIIB in five cases, and IV in three cases. The size of tumors on MRI was the most common, with 19 cases of 5–10 cm. Twenty-three cases of fascial tail signs were observed in preoperative MRI.
Conclusion
Among the patients with MFS, the local recurrence rate was high in the group with a fascial tail sign on MRI, and the overall survival and local free survival were significantly lower in the group with the fascial tail sign. Patients with MRI symptoms of a fascial tail sign are more likely to recur, so a longer and wider resection margin should be secured and resected.
